Discover how a single genetic variation, the CYP3A4*1B polymorphism, could be the key to optimizing treatment with haloperidol for those battling the intense realities of acute alcoholic hallucinosis.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Relationship of CYP3A4*1B Single Nucleotide Polymorphism to the Efficiency and Safety Profiles of Haloperidol in Patients Enduring Acute Alcoholic Hallucinosis.
Parkhomenko et al., Psychopharmacol Bull 2023
PMID: 38076668
Listen, folks, we’ve got this drug, haloperidol, it’s huge for treating people with acute alcoholic hallucinosis. But let me tell you, there’s been talk, lots of talk, about side effects, really not good. Now, there’s this gene, CYP3A4*1B, with a polymorphism, 392A > G, it’s a big deal, it could change how the drug works, how safe it is, believe me.
We took a look, a serious look, at 100 men with this condition, average age 41.4, and we checked how well haloperidol worked using the best scales, PANSS for efficacy, UKU and SAS for safety – only the best. We did the genotyping with real-time PCR, very high-tech, very accurate.
And guess what we found? No difference, none, in how well the drug worked or how safe it was, whether they had the AA or AG genotype. The numbers, they don’t lie – efficacy, safety, all the same. The study, it’s clear, the 392A > G polymorphism, it doesn’t affect haloperidol in these patients. It’s true, it’s the best science. So when it comes to haloperidol and this gene, you can forget about it, it’s not a problem. We did the work, we have the best people, and that’s just the way it is.